Welcome to this week's Chutes and Ladders, our roundup of hirings and retirings throughout the industry. Please send the good word--or the bad--from your shop to Michael Gibney (email | Twitter) or Amirah Al Idrus (email | Twitter), and we will feature it here at the end of each week.
After Teva shakeup, Yitzhak Peterburg steps up as chairman
Teva ($TEVA), whose board composition has stirred up some recent shareholder activism, has picked its next chairman. And investors pushing for more experienced leadership may be pleased with his resume. Current board member Yitzhak Peterburg will step in Jan. 1 for controversial chairman Phillip Frost, who over the summer announced he'd be leaving his post amid a boardroom revamp. Unlike his predecessor, Peterburg has some experience in the pharma and healthcare spaces: Before joining Teva's board nearly three years ago, he served as the company's VP of global branded products and helmed Clalit Health Services, Israel's leading healthcare provider. More
Biotech > Just a few months after Ron Renaud completed the sale of Idenix to Merck ($MRK) for $3.85 billion, the biotech CEO's vacation is officially over. Instead, he's opening a new chapter in his career--taking the helm at the upstart RaNA in Cambridge, MA, and switching focus from hepatitis C to long noncoding RNA. Story > Biocept ($BIOC) appointed Dr. Veena Singh as medical director. Release > Ocera Therapeutics ($OCRX) promoted Michael Byrnes to chief financial officer. Release > Institut Pasteur appointed Isabelle Buckle as EVP of research applications and industrial partnerships and Pierre Legrain as EVP of academic development and grant office. Release > Qu Biologics welcomed gastroenterologist Dr. Remo Panaccione to its inflammatory bowel disease advisory team. Release > DuPont ($DD) named Matthias Heinzel as president of DuPont nutrition and health. Release > CMC Biologics appointed Joseph Wypych as general manager of its Seattle facility. Release > Intrexon ($XON) announced the appointment of Peter Emtage as vice president of synthetic immunology. Release > Neogen ($NEOG) named Richard Calk as COO. Release > Pronutria appointed Peter Mueller as president of R&D and chief scientific officer. Release > SynGen hired David Hodl, formerly of Becton Dickinson ($BDX), as president of its cell processing business unit. Release > Jeremy Caldwell joined Ardelyx as the company's executive vice president and chief scientific officer. Release > The AVA Group brought on Stefan Krawielitzki as an organic chemistry expert. Release > Aridis Pharmaceuticals appointed Dr. Steven Opal to its scientific advisory board. Release > BioClinica named John Hubbard as its new CEO. Release > Jeffrey Bluestone joined Juno Therapeutics as the company's scientific adviser. Release > Apricus Biosciences appointed Brian Dorsey as its chief development officer. Release > QLT's ($QLTI) chief financial officer, Sukhi Jagpal, has left the company. Release > Dimension Therapeutics, a 2014 Fierce 15 company, named Dr. Eric Crombez as the company's chief medical officer. Release > Idera Pharmaceuticals ($IDRA) hired Vincent Milano as its CEO. Release > Optio Labs brought on Gregg Smith as its CEO. Release > Proteostasis Therapeutics named Dr. Po-Shun Lee as vice president of clinical development. Release > Foundation Medicine ($FMI) appointed David Daly as chief commercial officer. Release > Osiris Therapeutics ($OSIR) is expanding its management team with the appointment of Adrian Mollo as general counsel and Dr. Jon Hopper as chief medical officer. Release Pharma > Teva's ($TEVA) board of directors appointed Dr. Sol Barer, former CEO of Celgene ($CELG), as a director, effective Jan. 1, 2015. Release > Afferent Pharma announces the election of K. Peter Hirth to its board of directors. Release Pharma Manufacturing > SOHM announced the appointment of G. Michael Bennett as chair of the advisory board team. Release Animal Health > Jaguar Animal Health has appointed Tim Dotson to head Regulatory Affairs. Release Medical Devices > Acton, MA-based Cognoptix, developer of an eye test for diagnosing Alzheimer's disease, has appointed Barry Greenberg to its clinical advisory board. Release |
||||||||||
